Concepedia

Liangxian Cao

LC

Statistics

Publications

17

Citations

1.1K

H-Index

14

Active since

1997

Affiliations

PTC Therapeutics (United States)(Current)

University of Toronto

University of Oklahoma Health Sciences Center

University of Oklahoma

Oklahoma City University

Liangxian Cao is an author at PTC Therapeutics (United States) specializing in molecular oncology, oncology, and medicine.

ORCID

Publications per year

1997–2024

17

Publications

17

Self-renewal as a therapeutic target in human colorectal cancer

Antonija Kreso, Peter van Galen, Nicholas Pedley et al. · Nature Medicine · 2013 · 534 citations

, , +14

Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties

Liangxian Cao, Marla Weetall, Christopher R. Trotta et al. · Molecular Cancer Therapeutics · 2018 · 85 citations

, , +14

The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines

Jeremy Luban, Rachel A. Sattler, Elke Mühlberger et al. · Virus Research · 2020 · 73 citations · Full text

, , +12

BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer

Nitu Bansal, Monica Bartucci, Shamila Yusuff et al. · Clinical Cancer Research · 2016 · 57 citations · Full text

, , +17

Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression

Kol Jia Yong, Daniela S. Daniela Sanchez Bassères, Robert S. Welner et al. · Science Translational Medicine · 2016 · 52 citations · Full text

, , +11

1–5 of 17